Key Insights on the Impact of Sacubitril–Valsartan in Canada, Despite Limitations of Registry Data
Michael A McDonald, Melanie Kok, Anique Ducharme, Justin Ezekowitz, Jonathan Howlett, Carlos Rojas-Fernandez, Jacob A Udell · 2026
Read Key Insights on the Impact of Sacubitril–Valsartan in Canada, Despite Limitations of Registry Data by Michael A McDonald, Melanie Kok, Anique Ducharme, Justin Ezekowitz, Jonathan Howlett, Carlos Rojas-Fernandez, Jacob A Udell (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13386727.txt.
Description
Michael McDonald and co-authors answer a critic in a 2026 letter about their Canadian heart failure registry. The registry followed real-world patients starting the drug sacubitril-valsartan, and a correspondent had pressed on its methods, including how few participants got a key blood test at entry.
The authors concede the limits openly: only about a third had baseline natriuretic peptide testing, which blocks firm claims linking those values to outcomes. They note the gap itself documents uneven test access in Canada. Within those bounds, they say, the registry still reassures that the drug proved safe, tolerated, and effective in everyday practice.
Catalog record
| CREATOR | Michael A McDonald, Melanie Kok, Anique Ducharme, Justin Ezekowitz, Jonathan Howlett, Carlos Rojas-Fernandez, Jacob A Udell |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 4 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |